https://www.pharmaceutical-technology.com/data-insights/bay-2416964-bayer-solid-tumor-likelihood-of-approval/ 2024-06-18T06:44:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senti-202-senti-biosciences-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-23T02:09:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senti-202-senti-biosciences-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-23T02:09:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senti-202-senti-biosciences-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-23T02:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ncp-112-novacell-technology-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-23T02:09:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/givastomig-i-mab-solid-tumor-likelihood-of-approval/ 2024-06-18T06:42:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/givastomig-i-mab-gastric-cancer-likelihood-of-approval/ 2024-06-18T06:42:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temozolomide-orphelia-pharma-malignant-glioma-likelihood-of-approval/ 2025-01-23T02:09:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temozolomide-orphelia-pharma-rhabdomyosarcoma-likelihood-of-approval/ 2025-01-23T02:09:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temozolomide-orphelia-pharma-medulloblastoma-likelihood-of-approval/ 2025-01-23T02:09:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temozolomide-orphelia-pharma-anaplastic-astrocytoma-likelihood-of-approval/ 2025-01-23T02:09:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temozolomide-orphelia-pharma-ewing-sarcoma-likelihood-of-approval/ 2025-01-23T02:09:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4685-ono-pharmaceutical-follicular-lymphoma-likelihood-of-approval/ 2025-01-23T02:09:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mometasone-furoate-esocap-eosinophilic-esophagitis-likelihood-of-approval/ 2024-07-06T05:14:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emfizatamab-systimmune-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-23T02:09:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/escharex-second-generation-mediwound-diabetic-foot-ulcers-likelihood-of-approval/ 2025-01-23T02:08:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agen-1571-agenus-solid-tumor-likelihood-of-approval/ 2024-06-18T06:39:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pilocarpine-glaukos-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-06-18T06:37:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dd-01-d-d-pharmatech-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2025-01-22T18:19:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-09-09T06:59:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-celltrion-allergic-asthma-likelihood-of-approval/ 2025-01-22T18:19:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-celltrion-food-allergy-likelihood-of-approval/ 2025-01-22T18:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-celltrion-nasal-polyps-nasal-polyposis-likelihood-of-approval/ 2025-01-22T18:18:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-celltrion-rhinosinusitis-likelihood-of-approval/ 2025-01-22T18:18:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-celltrion-chronic-urticaria-or-hives-likelihood-of-approval/ 2025-01-22T18:18:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-315-merck-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-07-06T05:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-315-merck-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-07-06T05:14:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-315-merck-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-07-06T05:14:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-315-merck-esophageal-cancer-likelihood-of-approval/ 2024-07-06T05:14:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebx-102-enterobiotix-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-06-18T06:33:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebx-102-enterobiotix-myelodysplastic-syndrome-likelihood-of-approval/ 2024-06-18T06:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebx-102-enterobiotix-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2024-06-18T06:33:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebx-102-enterobiotix-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-06-18T06:32:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebx-102-enterobiotix-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-06-18T06:32:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/or-2805-oncoresponse-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-18T06:32:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-337395-shionogi-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-09-09T06:59:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dx-126262-hangzhou-dac-biotech-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-22T18:18:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dx-126262-hangzhou-dac-biotech-ureter-cancer-likelihood-of-approval/ 2025-01-22T18:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dx-126262-hangzhou-dac-biotech-bladder-cancer-likelihood-of-approval/ 2025-01-22T18:18:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dx-126262-hangzhou-dac-biotech-gastric-cancer-likelihood-of-approval/ 2025-01-22T18:18:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dx-126262-hangzhou-dac-biotech-breast-cancer-likelihood-of-approval/ 2025-01-22T18:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:18:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hh-2853-shanghai-haihe-biopharma-sarcomas-likelihood-of-approval/ 2024-06-18T06:28:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/measles-strain-edmonstons-zagreb-rubella-strain-ra-27-vaccine-micron-biomedical-rubella-german-measles-likelihood-of-approval/ 2024-06-18T06:28:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/measles-strain-edmonstons-zagreb-rubella-strain-ra-27-vaccine-micron-biomedical-measles-likelihood-of-approval/ 2024-06-18T06:28:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986288-bristol-myers-squibb-melanoma-likelihood-of-approval/ 2024-06-18T06:27:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-1-stero-biotechs-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-06-18T06:27:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-3563254-bayer-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T18:18:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/u-51-shanghai-unicar-therapy-bio-medicine-technology-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2025-01-22T18:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:17:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cu-06-thea-open-innovation-sasu-diabetic-macular-edema-likelihood-of-approval/ 2025-01-22T18:17:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ty-302-tetranov-international-ovarian-cancer-likelihood-of-approval/ 2025-01-22T18:17:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-slamf7-for-multiple-myeloma-t-curx-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-06-18T06:25:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsbr-1290-structure-therapeutics-type-2-diabetes-likelihood-of-approval/ 2025-01-22T18:17:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsbr-1290-structure-therapeutics-obesity-likelihood-of-approval/ 2025-01-22T18:17:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbl-015-leads-biolabs-lymphoma-likelihood-of-approval/ 2025-01-22T18:17:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ata-2271-atara-biotherapeutics-malignant-pleural-mesothelioma-likelihood-of-approval/ 2024-06-18T06:24:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ata-2271-atara-biotherapeutics-solid-tumor-likelihood-of-approval/ 2024-06-18T06:23:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hrain-002-hrain-biotechnology-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-18T06:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hrain-002-hrain-biotechnology-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-18T06:23:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/au-409-auransa-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-06-18T06:23:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vepafestinib-helsinn-healthcare-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:17:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vepafestinib-helsinn-healthcare-solid-tumor-likelihood-of-approval/ 2025-01-22T18:17:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biottt-001-beijing-thrite-biotechnology-peritoneal-cancer-likelihood-of-approval/ 2025-01-22T18:17:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/e-2511-eisai-alzheimer-s-disease-likelihood-of-approval/ 2025-01-22T18:17:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ose-279-ose-immunotherapeutics-thyroid-cancer-likelihood-of-approval/ 2025-01-22T18:17:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pna-1-proneurogen-traumatic-brain-injury-likelihood-of-approval/ 2024-06-18T06:19:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pna-5-proneurogen-traumatic-brain-injury-likelihood-of-approval/ 2024-06-18T06:19:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elritercept-keros-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-09-09T06:59:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/misetionamide-panavance-therapeutics-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-06-18T06:17:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epinephrine-ars-pharmaceuticals-chronic-urticaria-or-hives-likelihood-of-approval/ 2025-01-22T18:17:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retatrutide-eli-lilly-and-co-obesity-likelihood-of-approval/ 2025-01-22T18:17:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pl-9643-palatin-technologies-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-09-09T06:59:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xaluritamig-amgen-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T18:16:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etavopivat-novo-nordisk-anemia-likelihood-of-approval/ 2024-06-18T06:15:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selvigaltin-galecto-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-22T18:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tamuzimod-ventyx-biosciences-ulcerative-colitis-likelihood-of-approval/ 2025-01-22T18:16:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baxdrostat-astrazeneca-resistant-hypertension-likelihood-of-approval/ 2025-01-22T18:16:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baxdrostat-astrazeneca-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2025-01-22T18:16:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nilk-2301-lamkap-bio-group-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-18T05:56:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nilk-2301-lamkap-bio-group-solid-tumor-likelihood-of-approval/ 2024-06-18T05:55:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wma-1-wellmarker-bio-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-18T05:55:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wma-1-wellmarker-bio-solid-tumor-likelihood-of-approval/ 2024-06-18T05:55:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-614-novartis-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-22T18:16:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/frespaciguat-merck-idiopathic-pulmonary-hypertension-likelihood-of-approval/ 2025-01-22T18:16:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-67670187-johnson-johnson-inflammatory-bowel-disease-likelihood-of-approval/ 2024-06-18T05:52:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-67670187-johnson-johnson-ulcerative-colitis-likelihood-of-approval/ 2024-06-18T05:52:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emraclidine-cerevel-therapeutics-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2025-01-22T18:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adc-2122-hangzhou-adcoris-biopharmaceutical-gastric-cancer-likelihood-of-approval/ 2025-01-22T18:16:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retlirafusp-alfa-jiangsu-hengrui-medicine-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:16:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retlirafusp-alfa-jiangsu-hengrui-medicine-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:16:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retlirafusp-alfa-jiangsu-hengrui-medicine-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-22T18:16:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retlirafusp-alfa-jiangsu-hengrui-medicine-melanoma-likelihood-of-approval/ 2025-01-22T18:16:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T18:16:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2025-01-22T18:15:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:15:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-22T18:15:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T18:15:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-22T18:15:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camonsertib-repare-therapeutics-breast-cancer-likelihood-of-approval/ 2025-01-22T18:15:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ksq-4279-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2025-01-22T18:15:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orforglipron-calcium-eli-lilly-and-co-obesity-likelihood-of-approval/ 2025-01-22T18:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tg-4050-transgene-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-22T18:15:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tg-4050-transgene-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-22T18:15:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tg-4050-transgene-laryngeal-cancer-likelihood-of-approval/ 2025-01-22T18:15:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tg-4050-transgene-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T18:15:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/equecabtagene-autoleucel-nanjing-iaso-biotherapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-22T18:15:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/equecabtagene-autoleucel-nanjing-iaso-biotherapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-22T18:14:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/slate-001-gritstone-bio-gastrointestinal-tumor-likelihood-of-approval/ 2025-01-22T18:14:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/slate-001-gritstone-bio-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-22T18:14:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/slate-001-gritstone-bio-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-22T18:14:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imgn-151-immunogen-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-22T18:14:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imgn-151-immunogen-peritoneal-cancer-likelihood-of-approval/ 2025-01-22T18:14:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imgn-151-immunogen-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-22T18:14:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stx-001-strand-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-06T05:12:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stx-001-strand-therapeutics-solid-tumor-likelihood-of-approval/ 2024-07-06T05:12:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stx-001-strand-therapeutics-melanoma-likelihood-of-approval/ 2024-07-06T05:12:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbt-508-newbio-therapeutics-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:58:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rovadicitinib-sino-biopharmaceutical-hemophagocytic-lymphohistiocytosis-likelihood-of-approval/ 2025-01-22T18:14:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monlunabant-inversago-pharma-obesity-likelihood-of-approval/ 2025-01-22T18:14:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monlunabant-inversago-pharma-metabolic-syndrome-likelihood-of-approval/ 2025-01-22T18:14:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/supernitro-attgeno-pulmonary-embolism-likelihood-of-approval/ 2024-06-18T05:37:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rimo-401-coordination-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T18:14:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exl-01-exeliom-biosciences-gastric-cancer-likelihood-of-approval/ 2025-01-22T18:14:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-002-shanghai-miracogen-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-22T18:14:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-002-shanghai-miracogen-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-22T18:13:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-002-shanghai-miracogen-gastric-cancer-likelihood-of-approval/ 2025-01-22T18:13:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-7827-f-hoffmann-la-roche-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-18T05:34:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-7827-f-hoffmann-la-roche-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-18T05:34:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-7827-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2024-06-18T05:33:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/delpacibart-etedesiran-avidity-biosciences-myotonic-dystrophy-likelihood-of-approval/ 2025-01-22T18:13:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elzovantinib-bristol-myers-squibb-central-nervous-system-cns-tumor-likelihood-of-approval/ 2025-01-22T18:13:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elzovantinib-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2025-01-22T18:13:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elzovantinib-bristol-myers-squibb-colorectal-cancer-likelihood-of-approval/ 2025-01-22T18:13:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1008-coherent-biopharma-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-07-06T05:11:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zipalertinib-taiho-pharmaceutical-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:12:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T18:12:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T18:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T18:12:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-thyroid-cancer-likelihood-of-approval/ 2025-01-22T18:12:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-gallbladder-cancer-likelihood-of-approval/ 2025-01-22T18:12:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:12:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-solid-tumor-likelihood-of-approval/ 2025-01-22T18:12:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-sarcomas-likelihood-of-approval/ 2025-01-22T18:11:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:11:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-bladder-cancer-likelihood-of-approval/ 2025-01-22T18:11:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-gastric-cancer-likelihood-of-approval/ 2025-01-22T18:11:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-colon-cancer-likelihood-of-approval/ 2025-01-22T18:11:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95035-les-laboratoires-servier-solid-tumor-likelihood-of-approval/ 2025-01-22T18:11:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-22T18:11:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T18:11:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T18:11:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-sarcomas-likelihood-of-approval/ 2025-01-22T18:11:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-bladder-cancer-likelihood-of-approval/ 2025-01-22T18:11:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-gastric-cancer-likelihood-of-approval/ 2025-01-22T18:11:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-prostate-cancer-likelihood-of-approval/ 2025-01-22T18:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-breast-cancer-likelihood-of-approval/ 2025-01-22T18:10:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-bispsma-clarity-pharmaceuticals-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T18:10:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clobetasol-propionate-afyx-therapeutics-vulvar-lichen-sclerosus-likelihood-of-approval/ 2025-01-22T18:10:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-07-06T05:10:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/narlumosbart-cspc-pharmaceutical-group-giant-cell-tumor-of-bone-likelihood-of-approval/ 2024-09-09T06:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/narlumosbart-cspc-pharmaceutical-group-humoral-hypercalcemia-of-malignancy-likelihood-of-approval/ 2024-09-09T06:57:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zxbt-1158-guangzhou-bebetter-medicine-technology-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-18T05:22:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zxbt-1158-guangzhou-bebetter-medicine-technology-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-06-18T05:21:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zxbt-1158-guangzhou-bebetter-medicine-technology-follicular-lymphoma-likelihood-of-approval/ 2024-06-18T05:21:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zxbt-1158-guangzhou-bebetter-medicine-technology-mantle-cell-lymphoma-likelihood-of-approval/ 2024-06-18T05:21:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zxbt-1158-guangzhou-bebetter-medicine-technology-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-18T05:21:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glpg-3667-galapagos-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-22T18:10:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glpg-3667-galapagos-ulcerative-colitis-likelihood-of-approval/ 2025-01-22T18:10:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tern-701-terns-pharmaceuticals-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T18:10:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexotegrast-pliant-therapeutics-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-22T18:10:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/st-002-sterotherapeutics-cushing-s-syndrome-likelihood-of-approval/ 2024-06-18T05:19:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046049-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-18T05:17:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046049-pfizer-metastatic-melanoma-likelihood-of-approval/ 2024-06-18T05:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-329-amgen-rheumatic-disorders-likelihood-of-approval/ 2025-01-22T18:10:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-329-amgen-sicca-syndrome-sjogren-likelihood-of-approval/ 2025-01-22T18:10:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fcn-437c-fochon-pharmaceutical-breast-cancer-likelihood-of-approval/ 2025-01-22T18:10:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dp-303c-cspc-pharmaceutical-group-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-09-09T06:57:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dp-303c-cspc-pharmaceutical-group-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-09-09T06:57:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dp-303c-cspc-pharmaceutical-group-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T06:57:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dp-303c-cspc-pharmaceutical-group-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T06:57:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dp-303c-cspc-pharmaceutical-group-metastatic-breast-cancer-likelihood-of-approval/ 2024-09-09T06:57:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ide-161-ideaya-biosciences-colorectal-cancer-likelihood-of-approval/ 2025-01-22T18:10:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ag-181-agios-pharmaceuticals-phenylketonuria-pku-likelihood-of-approval/ 2024-06-18T05:13:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-06T05:10:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-esophageal-cancer-likelihood-of-approval/ 2024-07-06T05:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-06T05:10:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-gastric-cancer-likelihood-of-approval/ 2024-07-06T05:09:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2024-07-06T05:09:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-melanoma-likelihood-of-approval/ 2024-07-06T05:09:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2024-07-06T05:09:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-prostate-cancer-likelihood-of-approval/ 2024-07-06T05:09:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salutaxel-shenzhen-salubris-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2024-07-06T05:09:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/romiplostim-biosimilar-qilu-pharmaceutical-thrombocytopenia-likelihood-of-approval/ 2024-06-18T05:10:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T18:10:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-synovial-sarcoma-likelihood-of-approval/ 2025-01-22T18:09:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-peritoneal-cancer-likelihood-of-approval/ 2025-01-22T18:09:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-22T18:09:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-22T18:09:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:09:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-endometrial-cancer-likelihood-of-approval/ 2025-01-22T18:09:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:09:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-melanoma-likelihood-of-approval/ 2025-01-22T18:09:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-ovarian-cancer-likelihood-of-approval/ 2025-01-22T18:09:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inetagugene-geperpavec-krystal-biotech-harlequin-ichthyosis-autosomal-recessive-congenital-ichthyosis-4b-likelihood-of-approval/ 2024-06-18T05:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-704-biomed-industries-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2025-01-22T18:09:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-3927-moderna-propionic-acidemia-likelihood-of-approval/ 2024-06-18T05:04:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zorevunersen-sodium-stoke-therapeutics-dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-likelihood-of-approval/ 2024-06-18T05:03:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-biosimilar-cstone-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2025-01-22T18:09:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/descartes-15-cartesian-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-22T18:09:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/descartes-15-cartesian-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-22T18:09:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-120-crispr-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-18T05:01:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-120-crispr-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-18T05:01:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eflornithine-kc-pharma-neuroblastoma-likelihood-of-approval/ 2024-09-09T06:56:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpn-217-merck-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-18T04:06:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpn-217-merck-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-18T04:05:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-compass-pathways-post-traumatic-stress-disorder-ptsd-likelihood-of-approval/ 2025-01-22T18:09:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-strains-a-h1n1-a-h3n2-b-victoria-b-yamagata-quadrivalent-split-virion-vaccine-sinovac-biotech-seasonal-influenza-likelihood-of-approval/ 2025-01-22T18:08:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dodekin-philogen-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-06-18T04:04:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tcr-800-t-cure-bioscience-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-06-18T04:04:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opc-415-otsuka-pharmaceutical-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-18T04:04:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/as-1763-carna-biosciences-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T18:08:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atr-12-azitra-netherton-syndrome-trichorrhexis-invaginata-bamboo-hair-likelihood-of-approval/ 2024-06-18T04:03:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inz-701-inozyme-pharma-end-stage-kidney-disease-end-stage-renal-disease-or-esrd-likelihood-of-approval/ 2025-01-22T18:08:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inz-701-inozyme-pharma-calciphylaxis-likelihood-of-approval/ 2025-01-22T18:08:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nv-5138-navitor-pharmaceuticals-major-depressive-disorder-likelihood-of-approval/ 2024-06-18T04:02:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quemliclustat-arcus-biosciences-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:08:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/giredestrant-genentech-usa-solid-tumor-likelihood-of-approval/ 2025-01-22T18:08:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonigutamab-ugodotin-laboratoires-pierre-fabre-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:08:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonigutamab-ugodotin-laboratoires-pierre-fabre-laryngeal-cancer-likelihood-of-approval/ 2025-01-22T18:08:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonigutamab-ugodotin-laboratoires-pierre-fabre-soft-tissue-sarcoma-likelihood-of-approval-2/ 2025-01-22T17:19:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonigutamab-ugodotin-laboratoires-pierre-fabre-breast-cancer-likelihood-of-approval/ 2025-01-22T18:08:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regn-4336-regeneron-pharmaceuticals-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-18T03:58:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/conv-01-alpha-convergent-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T18:08:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-luye-pharma-group-osteoporosis-likelihood-of-approval/ 2024-06-18T03:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-hydrochloride-fujifilm-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:08:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zasocitinib-takeda-pharmaceutical-ulcerative-colitis-likelihood-of-approval/ 2025-01-22T18:08:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cambritaxestat-ionctura-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T18:08:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-8374-astellas-pharma-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-22T18:07:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/penpulimab-akeso-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T18:07:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/penpulimab-akeso-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-22T18:07:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/penpulimab-akeso-cervical-cancer-likelihood-of-approval/ 2025-01-22T18:07:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-22T18:07:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-signet-ring-cell-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-22T18:07:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-adenoid-squamous-cell-carcinoma-pseudoglandular-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-22T18:07:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-squamous-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2025-01-22T17:18:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2025-01-22T17:18:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tildacerfont-spruce-biosciences-congenital-adrenal-hyperplasia-adrenogenital-syndrome-likelihood-of-approval/ 2024-09-09T06:56:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986301-bristol-myers-squibb-melanoma-likelihood-of-approval/ 2025-01-22T18:07:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmpl-306-hutchison-medipharma-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-22T18:07:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hmpl-306-hutchison-medipharma-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-22T18:07:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ag-73305-allgenesis-biotherapeutics-diabetic-macular-edema-likelihood-of-approval/ 2024-06-18T03:49:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceftibuten-ledaborbactam-etzadroxil-venatorx-pharmaceuticals-pyelonephritis-likelihood-of-approval/ 2024-06-18T03:49:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceftibuten-ledaborbactam-etzadroxil-venatorx-pharmaceuticals-urinary-tract-infections-likelihood-of-approval/ 2024-06-18T03:49:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snp-630-sinew-pharma-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-07-06T05:07:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snp-610-sinew-pharma-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-07-06T05:07:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hhcyh-33-shanghai-haihe-biopharma-breast-cancer-likelihood-of-approval/ 2024-06-18T03:47:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/av-078-aeovian-pharmaceuticals-tuberous-sclerosis-likelihood-of-approval/ 2024-07-06T05:07:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/almb-0168-alamab-therapeutics-bone-metastasis-likelihood-of-approval/ 2025-01-22T18:07:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lt-1001-lumosa-therapeutics-post-operative-pain-likelihood-of-approval/ 2024-06-18T03:46:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orelabrutinib-innocare-pharma-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T18:06:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvilostomig-systimmune-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T18:06:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blb-01d1-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2025-01-22T17:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quavonlimab-merck-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-18T03:45:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/survodutide-boehringer-ingelheim-international-renal-failure-likelihood-of-approval/ 2025-01-22T18:06:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/befotertinib-inventisbio-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-22T18:06:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peptide-to-inhibit-cd200-for-oncology-ox2-therapeutics-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2025-01-22T18:06:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peptide-to-inhibit-cd200-for-oncology-ox2-therapeutics-high-grade-glioma-likelihood-of-approval/ 2025-01-22T18:06:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nitronazine-guangzhou-magpie-pharmaceutical-type-2-diabetes-likelihood-of-approval/ 2024-06-18T03:43:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/farletuzumab-ecteribulin-eisai-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-22T18:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/farletuzumab-ecteribulin-eisai-peritoneal-cancer-likelihood-of-approval/ 2025-01-22T18:06:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/farletuzumab-ecteribulin-eisai-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-22T18:06:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tirapazamine-teclison-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-22T18:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vornorexant-taisho-pharmaceutical-insomnia-likelihood-of-approval/ 2025-01-22T18:06:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T18:06:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:05:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:05:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-22T18:05:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niclosamide-pandomedx-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T18:05:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/og-6219-organon-co-endometriosis-likelihood-of-approval/ 2024-06-18T03:40:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986218-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-06-18T03:39:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lyt-200-puretech-health-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-06-18T03:39:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gq-1001-genequantum-healthcare-suzhou-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-07-06T05:07:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gq-1001-genequantum-healthcare-suzhou-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-06T05:07:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gq-1001-genequantum-healthcare-suzhou-gastric-cancer-likelihood-of-approval/ 2024-07-06T05:07:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/solbinsiran-sodium-eli-lilly-and-co-mixed-dyslipidemia-likelihood-of-approval/ 2025-01-22T18:05:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pl-18-jiangsu-protelight-pharmaceutical-biotechnology-bacterial-vaginosis-likelihood-of-approval/ 2025-01-22T18:05:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-8009-bicycle-therapeutics-ureter-cancer-likelihood-of-approval/ 2024-06-18T03:36:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-8009-bicycle-therapeutics-urethral-cancer-likelihood-of-approval/ 2024-06-18T03:35:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-8009-bicycle-therapeutics-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-06-18T03:35:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-5528-bicycle-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:05:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropidoxuridine-shuttle-pharmaceuticals-sarcomas-likelihood-of-approval/ 2025-01-22T18:05:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/travoprost-er-ocular-therapeutix-open-angle-glaucoma-likelihood-of-approval/ 2025-01-22T18:05:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/travoprost-er-ocular-therapeutix-ocular-hypertension-likelihood-of-approval/ 2025-01-22T18:05:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/e-2025-eisai-alzheimer-s-disease-likelihood-of-approval/ 2025-01-22T18:05:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etalanetug-eisai-alzheimer-s-disease-likelihood-of-approval/ 2025-01-22T18:05:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glofitamab-f-hoffmann-la-roche-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T18:05:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glofitamab-f-hoffmann-la-roche-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-22T18:04:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glofitamab-f-hoffmann-la-roche-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T18:04:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ost-122-oncostellae-ulcerative-colitis-likelihood-of-approval/ 2025-01-22T18:04:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golimumab-biosimilar-alvotech-inflammation-likelihood-of-approval/ 2025-01-22T18:04:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golimumab-biosimilar-alvotech-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-22T18:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexfadrostat-phosphate-damian-pharma-primary-hyperaldosteronism-likelihood-of-approval/ 2025-01-22T18:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zectivimod-lg-chem-ulcerative-colitis-likelihood-of-approval-2/ 2025-01-22T17:16:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-ascelia-pharma-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-09-09T06:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-ascelia-pharma-gastric-cancer-likelihood-of-approval/ 2024-09-09T06:55:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ec-313-evestra-endometriosis-likelihood-of-approval/ 2025-01-22T18:04:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arginine-sodium-succinate-polysan-atherosclerosis-likelihood-of-approval/ 2024-06-18T03:27:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemircopan-alexion-pharmaceuticals-iga-nephropathy-berger-s-disease-likelihood-of-approval/ 2024-06-18T03:27:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemircopan-alexion-pharmaceuticals-membranoproliferative-glomerulonephritis-type-ii-dense-deposit-disease-likelihood-of-approval/ 2024-06-18T03:27:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemircopan-alexion-pharmaceuticals-lupus-nephritis-likelihood-of-approval/ 2024-06-18T03:26:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemircopan-alexion-pharmaceuticals-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-06-18T03:26:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zagociguat-tisento-therapeutics-vascular-dementias-likelihood-of-approval/ 2025-01-22T18:04:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-22T18:04:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-22T18:04:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:04:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2025-01-22T18:04:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-colorectal-cancer-likelihood-of-approval/ 2025-01-22T18:04:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-breast-cancer-likelihood-of-approval/ 2025-01-22T18:03:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trgft-201-orca-biosystems-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T18:03:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daplusiran-tomligisiran-gsk-hepatitis-b-likelihood-of-approval/ 2025-01-22T18:03:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctt-1403-cancer-targeted-technology-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-18T03:21:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aumolertinib-mesylate-jiangsu-hansoh-pharmaceutical-group-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:03:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mazdutide-eli-lilly-and-co-type-2-diabetes-likelihood-of-approval/ 2025-01-22T18:03:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abl-105-abl-bio-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T18:03:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abl-105-abl-bio-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-22T18:03:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abl-001-compass-therapeutics-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-22T18:03:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zegocractin-calcimedica-pancreatitis-likelihood-of-approval/ 2025-01-22T18:03:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rpl-301-rocket-pharmaceuticals-anemia-likelihood-of-approval/ 2024-06-18T03:18:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itepekimab-regeneron-pharmaceuticals-bronchiectasis-likelihood-of-approval/ 2025-01-22T18:03:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-efsitora-alfa-eli-lilly-and-co-type-2-diabetes-likelihood-of-approval/ 2025-01-22T18:03:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navacaprant-hydrochloride-neumora-therapeutics-bipolar-disorder-manic-depression-likelihood-of-approval/ 2024-06-18T03:17:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eu-204-eutilex-epstein-barr-virus-hhv-4-infections-likelihood-of-approval/ 2024-06-18T03:17:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sugemalimab-cstone-pharmaceuticals-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:03:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sugemalimab-cstone-pharmaceuticals-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-06-18T03:16:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lae-005-laekna-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T18:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonpiretigene-isteparvovec-nanoscope-therapeutics-retinitis-pigmentosa-retinitis-likelihood-of-approval/ 2024-06-18T03:16:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ascorbic-acid-renovion-bronchiectasis-likelihood-of-approval/ 2025-01-22T18:02:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/es-481-es-therapeutics-epilepsy-likelihood-of-approval/ 2024-06-18T03:15:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fp-020-foresee-pharmaceuticals-sarcoidosis-likelihood-of-approval/ 2025-01-22T18:02:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-peritoneal-cancer-likelihood-of-approval/ 2025-01-22T18:02:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-22T18:02:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-head-and-neck-cancer-likelihood-of-approval/ 2025-01-22T18:02:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-22T18:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-001-mage-biologics-ulcerative-colitis-likelihood-of-approval/ 2024-06-18T03:13:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/noraramtide-biohaven-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-06-18T03:13:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cam-101-cambium-bio-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-06-18T03:12:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/geptanolimab-apollomics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/domvanalimab-arcus-biosciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:02:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/depemokimab-gsk-hypereosinophilic-syndrome-likelihood-of-approval/ 2024-06-18T03:11:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/depemokimab-gsk-asthma-likelihood-of-approval/ 2024-06-18T03:11:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/reximmune-c2-genvivo-breast-cancer-likelihood-of-approval/ 2024-06-18T03:11:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orvacabtagene-autoleucel-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-18T03:10:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orvacabtagene-autoleucel-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-18T03:10:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bvac-c-cellid-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2025-01-22T18:02:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bvac-c-cellid-cervical-cancer-likelihood-of-approval/ 2025-01-22T18:02:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deudomperidone-cindome-pharma-diabetic-gastroparesis-likelihood-of-approval/ 2024-06-18T03:09:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-122-icell-gene-therapeutics-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-07-06T05:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exn-407-exonate-diabetic-retinopathy-likelihood-of-approval/ 2024-06-18T03:07:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dersimelagon-phosphate-mitsubishi-tanabe-pharma-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-07-06T05:05:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atp-128-boehringer-ingelheim-international-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-18T03:05:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-4157-moderna-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2025-01-22T18:01:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-4157-moderna-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-22T18:01:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azetukalner-xenon-pharmaceuticals-major-depressive-disorder-likelihood-of-approval/ 2024-06-18T03:04:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nm-002-novabiotics-community-acquired-pneumonia-likelihood-of-approval/ 2024-06-18T03:04:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/granite-001-gritstone-bio-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-06-18T03:03:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/granite-001-gritstone-bio-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-18T03:03:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/granite-001-gritstone-bio-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-06-18T03:03:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/granite-001-gritstone-bio-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-18T03:02:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alrizomadlin-ascentage-pharma-group-international-adenoid-cystic-carcinoma-acc-likelihood-of-approval/ 2025-01-22T18:01:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/choh-01-cho-pharma-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:54:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/choh-01-cho-pharma-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T06:54:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/choh-01-cho-pharma-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:54:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vamikibart-f-hoffmann-la-roche-uveitis-likelihood-of-approval/ 2024-07-06T05:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vamikibart-f-hoffmann-la-roche-diabetic-macular-edema-likelihood-of-approval/ 2024-07-06T05:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-22T18:01:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfp-14927-delta-fly-pharma-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T18:01:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hiv-serotype-ad26-trivalent-vaccine-johnson-johnson-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2025-01-22T18:00:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2025-01-22T17:13:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval-2/ 2025-01-22T17:13:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2025-01-22T17:13:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-esophageal-cancer-likelihood-of-approval-2/ 2025-01-22T17:13:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-22T17:59:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abiprubart-kiniksa-pharmaceuticals-rheumatoid-arthritis-likelihood-of-approval/ 2024-09-09T06:53:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbm-588-miyarisan-pharmaceutical-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-22T17:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rezpegaldesleukin-nektar-therapeutics-alopecia-areata-likelihood-of-approval/ 2025-01-22T17:59:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/als-205-alsonex-motor-neuron-diseases-likelihood-of-approval/ 2024-06-18T02:54:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/als-205-alsonex-parkinson-s-disease-likelihood-of-approval/ 2024-06-18T02:54:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epcoritamab-genmab-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-22T17:59:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epcoritamab-genmab-burkitt-lymphoma-likelihood-of-approval/ 2025-01-22T17:59:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epcoritamab-genmab-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T17:59:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-819-fate-therapeutics-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-09-09T06:53:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tovinontrine-cardurion-pharmaceuticals-systolic-heart-failure-likelihood-of-approval/ 2024-06-18T02:51:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-2029-cytomx-therapeutics-prostate-cancer-likelihood-of-approval/ 2024-06-18T02:51:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evt-801-kazia-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T17:59:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shr-2554-jiangsu-hengrui-medicine-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-22T17:59:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sym-023-les-laboratoires-servier-metastatic-bile-duct-cancer-likelihood-of-approval/ 2025-01-22T17:58:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2223-chia-tai-tianqing-pharmaceutical-group-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T17:58:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitiperstat-astrazeneca-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2025-01-22T17:58:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T17:58:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivmed-80-glaukos-keratoconus-likelihood-of-approval/ 2024-06-18T02:48:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T17:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T17:58:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-gastric-cancer-likelihood-of-approval/ 2025-01-22T17:58:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fidrisertib-succinate-ipsen-fibrodysplasia-ossificans-progressiva-myositis-ossificans-progressiva-likelihood-of-approval/ 2025-01-22T17:58:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izokibep-acelyrin-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-22T17:58:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/egfr-edv-plk-immunitybio-malignant-mesothelioma-likelihood-of-approval/ 2024-06-18T02:46:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/egfr-edv-plk-immunitybio-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-18T02:46:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cgx-1321-curegenix-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T17:58:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-uveal-melanoma-likelihood-of-approval/ 2024-09-09T06:53:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-09-09T06:53:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-09-09T06:53:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T06:53:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-09-09T06:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T06:53:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-germ-cell-tumors-likelihood-of-approval/ 2024-09-09T06:53:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-solid-tumor-likelihood-of-approval/ 2024-09-09T06:53:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-gastric-cancer-likelihood-of-approval/ 2024-09-09T06:52:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-cervical-cancer-likelihood-of-approval/ 2024-09-09T06:52:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trotabresib-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2025-01-22T17:58:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/petosemtamab-merus-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-22T17:58:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/petosemtamab-merus-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T17:58:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/petosemtamab-merus-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-22T17:57:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/petosemtamab-merus-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-22T17:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/petosemtamab-merus-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T17:57:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linvoseltamab-regeneron-pharmaceuticals-food-allergy-likelihood-of-approval/ 2025-01-22T17:57:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T17:57:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-hematological-tumor-likelihood-of-approval/ 2025-01-22T17:57:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-thyroid-cancer-likelihood-of-approval/ 2025-01-22T17:57:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2025-01-22T17:57:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-advanced-malignancy-likelihood-of-approval/ 2025-01-22T17:57:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-lymphoma-likelihood-of-approval/ 2025-01-22T17:57:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-lung-cancer-likelihood-of-approval/ 2025-01-22T17:57:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/renizgamglogene-autogedtemcel-editas-medicine-beta-thalassaemia-likelihood-of-approval/ 2025-01-22T17:57:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T17:57:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T17:57:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-uveal-melanoma-likelihood-of-approval/ 2025-01-22T17:56:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T17:56:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/ 2025-01-22T17:56:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2025-01-22T17:56:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-cervical-cancer-likelihood-of-approval/ 2025-01-22T17:56:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2025-01-22T17:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mavorixafor-x4-pharmaceuticals-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-09-09T06:51:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kj-14002-kukje-pharmaceutical-industry-open-angle-glaucoma-likelihood-of-approval/ 2025-01-22T17:56:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kj-14002-kukje-pharmaceutical-industry-ocular-hypertension-likelihood-of-approval/ 2025-01-22T17:56:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T17:56:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T17:56:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T17:56:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-22T17:56:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T17:55:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-22T17:55:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-laryngeal-cancer-likelihood-of-approval/ 2025-01-22T17:55:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T17:55:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-metastatic-melanoma-likelihood-of-approval/ 2025-01-22T17:55:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-gastric-cancer-likelihood-of-approval/ 2025-01-22T17:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1065845-neurocrine-biosciences-major-depressive-disorder-likelihood-of-approval/ 2024-06-18T02:30:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radspherin-oncoinvent-carcinomas-likelihood-of-approval/ 2025-01-22T17:55:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-leptomeningeal-disease-neoplastic-meningitis-leptomeningeal-carcinomatosis-likelihood-of-approval/ 2025-01-22T17:55:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-22T17:55:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-gallbladder-cancer-likelihood-of-approval/ 2025-01-22T17:55:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T17:55:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-breast-cancer-likelihood-of-approval/ 2025-01-22T17:54:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T17:54:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T17:54:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-gallbladder-cancer-likelihood-of-approval/ 2025-01-22T17:54:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T17:54:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/palupiprant-adlai-nortye-biopharma-rectal-cancer-likelihood-of-approval/ 2024-09-09T06:50:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ln-145-iovance-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T17:54:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T17:54:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtr-297-vanda-pharmaceuticals-onychomycosis-tinea-unguium-likelihood-of-approval/ 2025-01-22T17:54:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wegovy-novo-nordisk-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2025-01-22T17:54:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ruvembri-biophytis-obesity-likelihood-of-approval/ 2025-01-22T17:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balcinrenone-astrazeneca-liver-failure-hepatic-insufficiency-likelihood-of-approval/ 2024-07-06T05:01:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ota-201-onward-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-09-09T06:50:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ota-201-onward-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-09-09T06:50:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-101-mustang-bio-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-06-18T02:21:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hemay-022-tianjin-hemay-pharmaceutical-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-06-18T02:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mosunetuzumab-genentech-usa-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2025-01-22T17:08:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pertuzumab-biosimilar-organon-co-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-06-18T02:20:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serplulimab-shanghai-henlius-biotech-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T17:53:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-14-iksuda-therapeutics-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T17:53:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-14-iksuda-therapeutics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-22T17:53:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-14-iksuda-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-22T17:53:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-14-iksuda-therapeutics-gastric-cancer-likelihood-of-approval/ 2025-01-22T17:53:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-fulgent-pharma-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-09-09T06:50:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T17:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T17:52:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-gastric-cancer-likelihood-of-approval/ 2025-01-22T17:52:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xmt-2056-mersana-therapeutics-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T17:52:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xmt-2056-mersana-therapeutics-gastric-cancer-likelihood-of-approval/ 2025-01-22T17:52:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceb-01-cebiotex-liposarcoma-likelihood-of-approval/ 2025-01-22T17:52:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fluticasone-propionate-ellodi-pharmaceuticals-eosinophilic-esophagitis-likelihood-of-approval/ 2024-07-06T05:00:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belzutifan-merck-pancreatic-tumor-likelihood-of-approval/ 2025-01-22T17:52:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ppv-06-peptinov-inflammation-likelihood-of-approval/ 2024-06-18T02:15:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/carbidopa-levodopa-contera-pharma-parkinson-s-disease-likelihood-of-approval/ 2024-06-18T02:15:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivarmacitinib-sulfate-jiangsu-hengrui-medicine-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-22T17:52:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-innovent-biologics-recurrent-respiratory-papillomatosis-juvenile-laryngeal-papilloma-or-laryngeal-papilloma-likelihood-of-approval/ 2025-01-22T17:52:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mecbotamab-vedotin-bioatla-cervical-cancer-likelihood-of-approval/ 2025-01-22T17:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sofnobrutinib-carna-biosciences-skin-inflammation-likelihood-of-approval/ 2024-06-18T02:13:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/es-3000-escend-pharmaceuticals-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-22T17:52:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/es-3000-escend-pharmaceuticals-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-22T17:51:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/licaminlimab-oculis-anterior-uveitis-likelihood-of-approval/ 2025-01-22T17:51:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pelacarsen-sodium-novartis-aortic-valve-stenosis-likelihood-of-approval/ 2025-01-22T17:51:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T17:51:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-thyroid-cancer-likelihood-of-approval/ 2025-01-22T17:51:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-melanoma-likelihood-of-approval/ 2025-01-22T17:51:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-lymphoma-likelihood-of-approval/ 2025-01-22T17:51:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2025-01-22T17:51:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ap-101-al-s-pharma-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-06-18T02:07:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemigatinib-incyte-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2024-07-06T04:59:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemigatinib-incyte-breast-cancer-likelihood-of-approval/ 2024-07-06T04:59:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erfonrilimab-alphamab-oncology-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T17:51:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ravulizumab-la-alexion-pharmaceuticals-iga-nephropathy-berger-s-disease-likelihood-of-approval/ 2025-01-22T17:51:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anbenitamab-alphamab-oncology-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-22T17:51:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anbenitamab-alphamab-oncology-gastric-cancer-likelihood-of-approval/ 2025-01-22T17:51:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remygen-diamyd-medical-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2025-01-22T17:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cavrotolimod-bluejay-therapeutics-hepatitis-b-likelihood-of-approval/ 2025-01-22T17:50:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pr-001-prevail-therapeutics-gaucher-disease-type-i-likelihood-of-approval/ 2024-06-18T02:04:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brepocitinib-tosylate-priovant-therapeutics-non-infectious-uveitis-likelihood-of-approval/ 2025-01-22T17:50:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brepocitinib-tosylate-priovant-therapeutics-dermatomyositis-likelihood-of-approval/ 2025-01-22T17:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cagrilintide-novo-nordisk-type-2-diabetes-likelihood-of-approval/ 2025-01-22T17:50:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-3795-merck-von-hippel-lindau-syndrome-likelihood-of-approval/ 2025-01-22T17:50:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmoh-01-curatis-tension-type-headache-likelihood-of-approval/ 2025-01-22T17:50:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2025-01-22T17:50:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T17:48:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T17:48:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2025-01-22T17:48:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-myelofibrosis-likelihood-of-approval/ 2025-01-22T17:40:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/ 2025-01-22T17:40:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-essential-thrombocythemia-likelihood-of-approval/ 2025-01-22T17:40:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-polycythemia-vera-likelihood-of-approval/ 2025-01-22T17:39:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-merck-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-22T17:39:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/taletrectinib-adipate-nuvation-bio-solid-tumor-likelihood-of-approval/ 2025-01-22T17:39:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/taletrectinib-adipate-nuvation-bio-colorectal-cancer-likelihood-of-approval/ 2025-01-22T17:39:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ue-2343-actinogen-medical-alzheimer-s-disease-likelihood-of-approval/ 2025-01-22T17:39:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivs-1001-invectys-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T17:39:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivs-1001-invectys-vulvar-cancer-likelihood-of-approval/ 2025-01-22T17:39:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivs-1001-invectys-anal-cancer-likelihood-of-approval/ 2025-01-22T17:39:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivs-1001-invectys-cervical-cancer-likelihood-of-approval/ 2025-01-22T17:39:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ser-155-seres-therapeutics-bacteremia-likelihood-of-approval/ 2025-01-22T17:39:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986012-bristol-myers-squibb-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-18T01:54:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scp-776-silver-creek-pharmaceuticals-myocardial-infarction-likelihood-of-approval/ 2024-06-18T01:54:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-peritoneal-cancer-likelihood-of-approval/ 2025-01-22T17:39:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-22T17:39:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/proagio-proda-biotech-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-22T17:39:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-samyang-biopharmaceuticals-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-06-18T01:52:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relacorilant-corcept-therapeutics-cushing-s-syndrome-likelihood-of-approval/ 2025-01-22T17:38:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relacorilant-corcept-therapeutics-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/ 2025-01-22T17:38:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mezagitamab-takeda-pharmaceutical-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-06-18T01:51:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omilancor-nimmune-biopharma-ulcerative-colitis-likelihood-of-approval/ 2024-06-18T01:50:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glenzocimab-acticor-biotech-acute-ischemic-stroke-likelihood-of-approval/ 2024-06-18T01:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/soticlestat-takeda-pharmaceutical-dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-likelihood-of-approval/ 2025-01-22T17:38:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ad-214-adalta-kidney-fibrosis-likelihood-of-approval/ 2025-01-22T17:38:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kindolor-lohocla-research-pain-likelihood-of-approval/ 2024-06-18T01:47:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegadricase-swedish-orphan-biovitrum-gouty-arthritis-gout-likelihood-of-approval/ 2025-01-22T17:38:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oatd-01-molecure-pulmonary-sarcoidosis-likelihood-of-approval/ 2025-01-22T17:38:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazodalibep-amgen-sicca-syndrome-sjogren-likelihood-of-approval/ 2025-01-22T17:38:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emavusertib-hydrochloride-curis-metastatic-melanoma-likelihood-of-approval/ 2025-01-22T17:38:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nacubactam-nacugen-therapeutics-ventilator-associated-pneumonia-vap-likelihood-of-approval/ 2025-01-22T17:37:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nacubactam-nacugen-therapeutics-pyelonephritis-likelihood-of-approval/ 2024-06-18T01:44:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nacubactam-nacugen-therapeutics-complicated-intra-abdominal-infections-likelihood-of-approval/ 2025-01-22T17:37:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nacubactam-nacugen-therapeutics-urinary-tract-infections-likelihood-of-approval/ 2024-06-18T01:44:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilzabrutinib-sanofi-immunoglobulin-g4-related-disease-igg4-rd-likelihood-of-approval/ 2025-01-22T17:37:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilzabrutinib-sanofi-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2025-01-22T17:37:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilzabrutinib-sanofi-acquired-autoimmune-hemolytic-anemia-likelihood-of-approval/ 2025-01-22T17:37:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilzabrutinib-sanofi-chronic-urticaria-or-hives-likelihood-of-approval/ 2025-01-22T17:37:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilzabrutinib-sanofi-asthma-likelihood-of-approval/ 2025-01-22T17:37:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cipepofol-sichuan-haisco-pharmaceutical-general-anesthetic-effect-likelihood-of-approval/ 2024-06-18T01:42:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inclisiran-novartis-acute-coronary-syndrome-likelihood-of-approval/ 2025-01-22T17:37:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zifanocycline-kbp-biosciences-acinetobacter-infections-likelihood-of-approval/ 2024-06-19T17:00:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/eha-2024-astrazenecas-calquence-plus-chemoimmunotherapy-offers-new-standard-for-mcl/ 2024-06-17T19:54:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biosimilar-shanghai-henlius-biotech-follicular-lymphoma-likelihood-of-approval-2/ 2025-01-22T16:42:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-shanghai-henlius-biotech-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-22T17:37:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T17:37:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-22T17:36:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2025-01-22T17:36:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-22T17:36:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-solid-tumor-likelihood-of-approval/ 2025-01-22T17:36:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/feladilimab-gsk-metastatic-melanoma-likelihood-of-approval/ 2025-01-22T17:36:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-vedotin-abbvie-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:14:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-22T02:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T02:14:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T02:14:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-endometrial-cancer-likelihood-of-approval/ 2025-01-22T02:14:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-sarcomas-likelihood-of-approval/ 2025-01-22T02:14:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-bladder-cancer-likelihood-of-approval/ 2025-01-22T02:14:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-colorectal-cancer-likelihood-of-approval/ 2025-01-22T02:14:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-prostate-cancer-likelihood-of-approval/ 2025-01-22T02:14:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-ovarian-cancer-likelihood-of-approval/ 2025-01-22T02:14:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-breast-cancer-likelihood-of-approval/ 2025-01-22T02:14:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlitelimab-sanofi-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-22T02:14:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlitelimab-sanofi-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-22T02:14:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlitelimab-sanofi-asthma-likelihood-of-approval/ 2025-01-22T02:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onl-1204-onl-therapeutics-geographic-atrophy-likelihood-of-approval/ 2025-01-22T02:13:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibuprofen-trelamine-hydrochloride-techfields-pharma-osteoarthritis-pain-likelihood-of-approval/ 2024-06-17T17:25:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utidelone-biostar-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-06-17T17:25:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utidelone-biostar-pharmaceuticals-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-06-17T17:24:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utidelone-biostar-pharmaceuticals-gastric-cancer-likelihood-of-approval/ 2025-01-22T02:13:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bryostatin-1-synaptogenix-multiple-sclerosis-likelihood-of-approval/ 2025-01-22T02:13:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/faricimab-f-hoffmann-la-roche-non-proliferative-diabetic-retinopathy-npdr-likelihood-of-approval/ 2025-01-22T02:13:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/faricimab-f-hoffmann-la-roche-choroidal-neovascularization-likelihood-of-approval/ 2025-01-22T02:13:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prgn-3006-precigen-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:13:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prgn-3006-precigen-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:13:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-sodium-aztreonam-abbvie-hospital-acquired-pneumonia-hap-likelihood-of-approval/ 2025-01-22T02:13:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-sodium-aztreonam-abbvie-ventilator-associated-pneumonia-vap-likelihood-of-approval/ 2025-01-22T02:13:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-sodium-aztreonam-pfizer-pyelonephritis-likelihood-of-approval/ 2025-01-22T02:13:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-sodium-aztreonam-abbvie-bacterial-pneumonia-likelihood-of-approval/ 2025-01-22T02:13:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-sodium-aztreonam-abbvie-peritonitis-likelihood-of-approval/ 2024-06-17T17:21:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-sodium-aztreonam-abbvie-complicated-intra-abdominal-infections-likelihood-of-approval/ 2025-01-22T02:13:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-sodium-aztreonam-abbvie-gram-negative-bacterial-infections-likelihood-of-approval/ 2025-01-22T02:13:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-sodium-aztreonam-abbvie-urinary-tract-infections-likelihood-of-approval/ 2025-01-22T02:13:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:13:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-22T02:13:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tcmcb-07-endevica-bio-cancer-anorexia-cachexia-syndrome-likelihood-of-approval/ 2025-01-22T02:13:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:13:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:12:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-22T02:12:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T02:12:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-laryngeal-cancer-likelihood-of-approval/ 2025-01-22T02:12:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T02:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-22T02:12:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evorpacept-alx-oncology-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-22T02:12:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debio-0123-debiopharm-international-endometrial-cancer-likelihood-of-approval/ 2025-01-22T02:12:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avapritinib-blueprint-medicines-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:12:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avapritinib-blueprint-medicines-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:12:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anx-005-annexon-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2025-01-22T02:12:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arx-517-ambrx-biopharma-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T02:12:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldesleukin-iltoo-pharma-miscarriage-likelihood-of-approval/ 2025-01-22T02:11:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenebrutinib-genentech-usa-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T06:46:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenebrutinib-genentech-usa-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:46:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenebrutinib-genentech-usa-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:46:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenebrutinib-genentech-usa-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T06:46:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenebrutinib-genentech-usa-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:46:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6631-f-hoffmann-la-roche-autoimmune-disorders-likelihood-of-approval/ 2025-01-22T02:11:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zb-002-zenas-biopharma-usa-rheumatoid-arthritis-likelihood-of-approval/ 2024-06-17T17:09:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belvarafenib-genentech-usa-solid-tumor-likelihood-of-approval/ 2024-06-17T17:09:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dirloctocogene-samoparvovec-spark-therapeutics-hemophilia-a-factor-viii-deficiency-likelihood-of-approval/ 2024-06-17T17:08:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fs-222-f-star-therapeutics-melanoma-likelihood-of-approval/ 2025-01-22T02:11:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diacc-3010-evexta-bio-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:11:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diacc-3010-evexta-bio-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:11:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfp-11207-delta-fly-pharma-gallbladder-cancer-likelihood-of-approval/ 2024-07-06T04:55:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vc-01-vertex-pharmaceuticals-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-06-17T17:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anvatabart-opadotin-ambrx-biopharma-gastric-cancer-likelihood-of-approval/ 2024-07-06T04:55:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-7000-biohaven-partial-seizure-likelihood-of-approval/ 2025-01-22T02:11:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rtx-001-resolution-therapeutics-decompensated-cirrhosis-likelihood-of-approval/ 2025-01-22T02:11:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-09-09T06:45:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-09-09T06:45:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-09-09T06:45:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-solid-tumor-likelihood-of-approval/ 2024-09-09T06:45:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-hepatocellular-carcinoma-likelihood-of-approval/ 2024-09-09T06:45:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-gastric-cancer-likelihood-of-approval/ 2024-09-09T06:45:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-lymphoma-likelihood-of-approval/ 2024-09-09T06:45:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cedazuridine-decitabine-otsuka-pharmaceutical-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T02:11:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/elion-secures-81m-to-advance-antifungal-therapy/ 2024-06-17T17:02:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cedazuridine-decitabine-otsuka-pharmaceutical-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:11:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosifloxuridine-nafalbenamide-nucana-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-22T02:11:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fluticasone-propionate-eupraxia-pharmaceuticals-eosinophilic-esophagitis-likelihood-of-approval/ 2025-01-22T02:11:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vxa-901-veraxa-biotech-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-06-17T16:58:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenalisib-rhizen-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T02:11:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenalisib-rhizen-pharmaceuticals-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-22T02:11:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenalisib-rhizen-pharmaceuticals-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-22T02:11:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenalisib-rhizen-pharmaceuticals-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:11:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenalisib-rhizen-pharmaceuticals-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T02:11:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezeprogind-alzprotect-progressive-supranuclear-palsy-likelihood-of-approval/ 2024-09-09T06:45:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/delpazolid-ligachem-biosciences-mycobacterium-infections-likelihood-of-approval/ 2025-01-22T02:11:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gc-3111a-gc-biopharma-pertussis-whooping-cough-likelihood-of-approval/ 2024-06-17T16:54:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/centanafadine-sr-otsuka-pharmaceutical-attention-deficit-hyperactivity-disorder-adhd-likelihood-of-approval/ 2024-09-09T06:45:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lpcn-1111-verity-pharmaceuticals-male-hypogonadism-likelihood-of-approval/ 2024-06-17T16:53:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2025-01-22T02:11:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenocutuzumab-merus-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenocutuzumab-merus-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:11:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenocutuzumab-merus-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:10:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osimertinib-mesylate-astrazeneca-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:10:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osimertinib-mesylate-astrazeneca-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-22T02:10:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osimertinib-mesylate-astrazeneca-lymphoma-likelihood-of-approval/ 2025-01-22T02:10:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itm-31-itm-isotope-technologies-munich-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-06-17T16:50:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pasireotide-la-recordati-hyperprolactinaemia-likelihood-of-approval/ 2024-06-17T16:50:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ianalumab-novartis-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-22T02:10:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rocatinlimab-kyowa-kirin-asthma-likelihood-of-approval/ 2025-01-22T02:10:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:10:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-biocad-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-17T16:47:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-108-les-laboratoires-servier-leukemia-likelihood-of-approval/ 2024-06-17T16:46:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tu-2218-tiumbio-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-06-17T16:46:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/poseltinib-hanmi-pharmaceuticals-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T02:10:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efruxifermin-akero-therapeutics-type-2-diabetes-likelihood-of-approval/ 2025-01-22T02:10:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imifoplatin-promontory-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T02:10:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulixertinib-biomed-valley-discoveries-hematological-tumor-likelihood-of-approval/ 2025-01-22T02:10:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemziviptadil-immunoforge-cardiomyopathy-likelihood-of-approval/ 2024-06-17T16:44:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemziviptadil-immunoforge-cystic-fibrosis-likelihood-of-approval/ 2024-06-17T16:44:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemziviptadil-immunoforge-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2024-06-17T16:44:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tazemetostat-hydrobromide-ipsen-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2025-01-22T02:10:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tazemetostat-hydrobromide-ipsen-chordoma-likelihood-of-approval/ 2025-01-22T02:10:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tazemetostat-hydrobromide-ipsen-chondrosarcoma-likelihood-of-approval/ 2025-01-22T02:10:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vinorelbine-tartrate-taiwan-liposome-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-06-17T16:38:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vinorelbine-tartrate-taiwan-liposome-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-06-17T16:38:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pirfenidone-avalyn-pharma-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-22T02:10:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dbv-135-dbv-technologies-milk-allergy-likelihood-of-approval/ 2024-07-05T19:01:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dbv-135-dbv-technologies-eosinophilic-esophagitis-likelihood-of-approval/ 2024-07-05T19:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vb-1016-nykode-therapeutics-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-22T02:10:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lanifibranor-inventiva-type-2-diabetes-likelihood-of-approval/ 2024-06-17T16:36:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-secondary-cns-lymphoma-likelihood-of-approval/ 2025-01-22T02:10:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-primary-cns-lymphoma-likelihood-of-approval/ 2025-01-22T02:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tanimilast-chiesi-farmaceutici-chronic-bronchitis-likelihood-of-approval/ 2025-01-22T02:10:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tanimilast-chiesi-farmaceutici-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2025-01-22T02:09:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabirnetug-acumen-pharmaceuticals-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2025-01-22T02:09:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabirnetug-acumen-pharmaceuticals-mild-cognitive-impairment-likelihood-of-approval/ 2025-01-22T02:09:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabirnetug-acumen-pharmaceuticals-alzheimer-s-disease-likelihood-of-approval/ 2025-01-22T02:09:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ziftomenib-kura-oncology-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-22T02:09:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pas-004-pasithea-therapeutics-neurofibromatoses-type-i-von-recklinghausen-s-disease-likelihood-of-approval/ 2025-01-22T02:09:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-836858-boehringer-ingelheim-international-relapsed-acute-myeloid-leukemia-likelihood-of-approval-2/ 2025-01-22T01:47:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-836858-boehringer-ingelheim-international-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2025-01-22T01:47:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-836858-boehringer-ingelheim-international-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-2/ 2025-01-22T01:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisocabtagene-maraleucel-bristol-myers-squibb-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:09:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erenumab-amgen-rosacea-likelihood-of-approval/ 2024-06-17T16:31:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vericiguat-bayer-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2024-06-17T16:31:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qbeco-qu-biologics-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T02:09:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qbeco-qu-biologics-ovarian-cancer-likelihood-of-approval/ 2025-01-22T02:09:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iodine-i-131-apamistamab-actinium-pharmaceuticals-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-22T02:09:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iodine-i-131-apamistamab-actinium-pharmaceuticals-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2025-01-22T02:09:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lae-001-laekna-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2025-01-22T02:09:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-low-grade-glioma-likelihood-of-approval/ 2025-01-22T02:09:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-22T02:09:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2025-01-22T02:09:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-gallbladder-cancer-likelihood-of-approval/ 2025-01-22T02:08:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-bladder-cancer-likelihood-of-approval/ 2025-01-22T02:08:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T02:08:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-652-evive-biotech-acute-liver-failure-likelihood-of-approval/ 2024-06-17T16:26:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-22T02:08:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:08:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-gastric-cancer-likelihood-of-approval/ 2025-01-22T02:08:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-cervical-cancer-likelihood-of-approval/ 2025-01-22T02:08:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senaparib-impact-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T02:08:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-301-benitec-biopharma-oculopharyngeal-muscular-dystrophy-likelihood-of-approval/ 2024-06-17T16:24:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T02:08:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefiderocol-sulfate-tosylate-shionogi-resistant-pseudomonas-aeruginosa-infections-likelihood-of-approval/ 2025-01-22T02:08:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefiderocol-sulfate-tosylate-shionogi-klebsiella-pneumoniae-infections-likelihood-of-approval/ 2025-01-22T02:08:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefiderocol-sulfate-tosylate-shionogi-enterobacteriaceae-infections-likelihood-of-approval/ 2025-01-22T02:08:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefiderocol-sulfate-tosylate-shionogi-acinetobacter-infections-likelihood-of-approval/ 2025-01-22T02:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efbemalenograstim-alfa-la-evive-biotech-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-22T02:08:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efbemalenograstim-alfa-la-evive-biotech-peritoneal-cancer-likelihood-of-approval/ 2025-01-22T02:08:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efbemalenograstim-alfa-la-evive-biotech-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-22T02:08:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efbemalenograstim-alfa-la-evive-biotech-cervical-cancer-likelihood-of-approval/ 2025-01-22T02:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/apac-leaps-ahead-in-adoptive-cell-therapy-space/ 2024-06-17T16:46:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aderamastat-foresee-pharmaceuticals-sarcoidosis-likelihood-of-approval/ 2025-01-22T02:08:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bimiralisib-torqur-actinic-solar-keratosis-likelihood-of-approval/ 2024-06-17T16:20:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-starpharma-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-07-05T19:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonelokimab-moonlake-immunotherapeutics-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-22T02:08:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-prestige-biopharma-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T02:07:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/satralizumab-f-hoffmann-la-roche-autoimmune-encephalitis-post-infectious-likelihood-of-approval/ 2025-01-22T02:07:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-22T02:07:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:07:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-22T02:07:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-laryngeal-cancer-likelihood-of-approval/ 2025-01-22T02:07:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-22T02:07:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-22T02:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:07:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T02:07:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gallbladder-cancer-likelihood-of-approval/ 2025-01-22T02:07:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T02:07:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:07:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:07:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-09-09T06:43:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dinutuximab-beta-recordati-neuroblastoma-likelihood-of-approval/ 2025-01-22T02:07:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isn-001-anterogen-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-06-17T16:13:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemcentinib-bergenbio-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-22T02:07:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemcentinib-bergenbio-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:07:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qbkpn-qu-biologics-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2024-06-17T16:12:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qbkpn-qu-biologics-respiratory-tract-infections-likelihood-of-approval/ 2024-06-17T16:11:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d-121-oblita-therapeutics-leishmaniasis-kala-azar-likelihood-of-approval/ 2024-06-17T16:10:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-06-17T16:10:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-06-17T16:10:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2024-06-17T16:10:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-kaposi-sarcoma-likelihood-of-approval/ 2024-06-17T16:09:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-urinary-tract-cancer-likelihood-of-approval/ 2024-06-17T16:09:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-oropharyngeal-cancer-likelihood-of-approval/ 2024-06-17T16:09:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-esophageal-tumor-likelihood-of-approval/ 2024-06-17T16:08:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-vulvar-cancer-likelihood-of-approval/ 2024-06-17T16:08:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-vaginal-cancer-likelihood-of-approval/ 2024-06-17T16:08:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-rectal-cancer-likelihood-of-approval/ 2024-06-17T16:07:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-penile-cancer-likelihood-of-approval/ 2024-06-17T16:07:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-06-17T16:07:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-anal-cancer-likelihood-of-approval/ 2024-06-17T16:07:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-cervical-cancer-likelihood-of-approval/ 2024-06-17T16:06:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-lung-cancer-likelihood-of-approval/ 2024-06-17T16:06:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vcn-01-theriva-biologics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-22T16:41:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/famitinib-jiangsu-hengrui-medicine-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T06:36:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/famitinib-jiangsu-hengrui-medicine-hepatocellular-carcinoma-likelihood-of-approval/ 2024-09-09T06:36:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/str-324-stragen-new-molecules-post-operative-pain-likelihood-of-approval/ 2024-06-17T16:03:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amisulpride-acacia-pharma-post-operative-nausea-and-vomiting-likelihood-of-approval/ 2025-01-22T16:41:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifetroban-cumberland-pharmaceuticals-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-22T16:41:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/darolutamide-orion-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T16:41:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifebemtinib-inxmed-nanjing-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2025-01-22T02:06:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2025-01-22T16:41:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naratuximab-emtansine-debiopharm-international-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T06:35:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naratuximab-emtansine-debiopharm-international-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:35:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naratuximab-emtansine-debiopharm-international-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:35:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorolanib-betta-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:41:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bold-100-bold-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-06-17T15:59:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-choriocarcinoma-gestational-trophoblastic-neoplasia-likelihood-of-approval/ 2025-01-22T16:41:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-22T16:41:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenecteplase-genentech-usa-acute-ischemic-stroke-likelihood-of-approval/ 2025-01-22T16:41:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvatirsen-sodium-astrazeneca-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-17T15:57:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvatirsen-sodium-astrazeneca-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-17T15:56:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvatirsen-sodium-astrazeneca-myelodysplastic-syndrome-likelihood-of-approval/ 2024-06-17T15:56:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvrgx-314-abbvie-diabetic-retinopathy-likelihood-of-approval/ 2025-01-22T16:41:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fipaxalparant-amgen-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-22T16:41:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enoblituzumab-macrogenics-rhabdomyosarcoma-likelihood-of-approval/ 2024-06-17T15:55:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enoblituzumab-macrogenics-neuroblastoma-likelihood-of-approval/ 2024-06-17T15:54:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linzagolix-choline-kissei-pharmaceutical-endometriosis-likelihood-of-approval/ 2025-01-22T16:41:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linzagolix-choline-kissei-pharmaceutical-pain-likelihood-of-approval/ 2025-01-22T16:41:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T16:40:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T16:40:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T16:40:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:40:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-22T16:40:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T16:40:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:40:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-22T16:40:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T16:40:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-metastatic-melanoma-likelihood-of-approval/ 2025-01-22T16:40:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:40:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-22T16:40:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-gastric-cancer-likelihood-of-approval/ 2025-01-22T16:40:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-pancreatic-cancer-likelihood-of-approval/ 2024-06-17T15:48:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-cervical-cancer-likelihood-of-approval/ 2025-01-22T16:39:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-prostate-cancer-likelihood-of-approval/ 2025-01-22T16:39:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/froniglutide-immunoforge-inclusion-body-myositis-ibm-likelihood-of-approval/ 2025-01-22T16:39:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vosoritide-biomarin-pharmaceutical-dwarfism-likelihood-of-approval/ 2024-09-09T06:34:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izorlisib-stemline-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-06-17T15:46:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izorlisib-stemline-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-17T15:46:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alpelisib-novartis-endometrial-cancer-likelihood-of-approval/ 2025-01-22T16:39:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dpv-001-ubivac-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-09-09T06:34:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vp-20621-destiny-pharma-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval/ 2024-06-17T15:45:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-22T16:39:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-chondrosarcoma-likelihood-of-approval-2/ 2025-01-22T02:05:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-osteosarcoma-likelihood-of-approval-2/ 2025-01-22T02:05:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-ovarian-cancer-likelihood-of-approval/ 2025-01-22T16:39:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-f-hoffmann-la-roche-endometrial-cancer-likelihood-of-approval/ 2025-01-22T16:39:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/givinostat-hydrochloride-italfarmaco-polycythemia-vera-likelihood-of-approval/ 2025-01-22T16:39:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neflamapimod-cervomed-alzheimer-s-disease-likelihood-of-approval/ 2025-01-22T16:39:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/liafensine-denovo-biopharma-treatment-resistant-depression-likelihood-of-approval/ 2024-06-17T15:40:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daxdilimab-amgen-alopecia-areata-likelihood-of-approval/ 2024-09-09T06:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daxdilimab-amgen-dermatomyositis-likelihood-of-approval/ 2024-09-09T06:34:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biotest-wins-fda-approval-for-plasma-protein-therapy/ 2024-06-17T15:36:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/beacon-therapeutics-agtc-501-vista/ 2024-06-17T15:31:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/npc-patients-awaiting-disease-modifying-drugs/ 2024-06-17T15:25:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/radiopharma-specialist-telix-pulls-last-minute-plug-on-232m-ipo/ 2024-06-17T15:20:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/t-cell-manufacturing-when-is-the-right-time-to-automate/ 2024-06-17T15:20:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-imfinzi-endometrial-cancer/ 2024-06-17T10:14:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/enveda-drug-discovery/ 2024-06-17T10:07:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novavax-fda-approval-covid-vaccine/ 2024-06-17T08:19:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-amgen-blincyto/ 2024-06-17T08:15:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daxdilimab-amgen-chronic-cutaneous-lupus-erythematosus-ccle-discoid-lupus-erythematosus-dle-likelihood-of-approval/ 2024-09-09T06:33:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daxdilimab-amgen-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/ 2024-09-09T06:33:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apalutamide-johnson-johnson-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T16:39:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dabrafenib-mesylate-novartis-follicular-thyroid-cancer-likelihood-of-approval/ 2025-01-22T16:39:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ferric-carboxymaltose-vifor-pharma-management-restless-legs-syndrome-likelihood-of-approval/ 2025-01-22T16:39:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afuresertib-hydrochloride-laekna-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-07-05T18:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afuresertib-hydrochloride-laekna-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-07-05T18:57:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/margetuximab-macrogenics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-22T16:39:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/margetuximab-macrogenics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T16:39:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/margetuximab-macrogenics-gastric-cancer-likelihood-of-approval/ 2025-01-22T16:39:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ismidenon-amyriad-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2024-06-17T08:03:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T16:39:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-papillary-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-22T16:38:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-low-grade-glioma-likelihood-of-approval/ 2025-01-22T16:38:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-22T16:38:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-rhabdomyosarcoma-likelihood-of-approval/ 2025-01-22T16:38:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-ewing-sarcoma-likelihood-of-approval/ 2025-01-22T16:38:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T16:38:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ofatumumab-novartis-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2024-06-17T08:00:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clascoterone-cosmo-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T16:38:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clascoterone-cosmo-pharmaceuticals-prostate-cancer-likelihood-of-approval/ 2025-01-22T16:38:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tnx-1900-tonix-pharmaceuticals-holding-binge-eating-disorder-likelihood-of-approval/ 2024-06-17T07:59:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-genentech-usa-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T16:38:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-genentech-usa-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-22T16:38:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afatinib-dimaleate-boehringer-ingelheim-international-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T16:38:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ascrinvacumab-kintor-pharmaceutical-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-22T16:38:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-metastatic-melanoma-likelihood-of-approval/ 2025-01-22T16:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/buparlisib-hydrochloride-adlai-nortye-biopharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T16:38:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onvansertib-fumarate-cardiff-oncology-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-22T16:38:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onvansertib-fumarate-cardiff-oncology-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:37:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorinostat-merck-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T16:37:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tabelecleucel-laboratoires-pierre-fabre-post-transplant-lymphoproliferative-disorder-likelihood-of-approval/ 2025-01-22T16:37:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tabelecleucel-laboratoires-pierre-fabre-solid-tumor-likelihood-of-approval/ 2025-01-22T16:37:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tabelecleucel-laboratoires-pierre-fabre-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T16:37:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tabelecleucel-laboratoires-pierre-fabre-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T16:37:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pexidartinib-hydrochloride-daiichi-sankyo-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2025-01-22T16:37:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pexidartinib-hydrochloride-daiichi-sankyo-sarcomas-likelihood-of-approval/ 2025-01-22T16:37:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/melphalan-hydrochloride-delcath-systems-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T16:37:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/actimab-a-actinium-pharmaceuticals-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T16:37:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/actimab-a-actinium-pharmaceuticals-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T16:37:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/actimab-a-actinium-pharmaceuticals-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-22T16:37:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nto-1151-ology-bioservices-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-22T16:37:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnz-2591-acadia-pharmaceuticals-rett-syndrome-likelihood-of-approval/ 2025-01-22T16:37:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnz-2591-neuren-pharmaceuticals-prader-willi-syndrome-pws-likelihood-of-approval/ 2024-06-17T07:44:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cv-7302-curevac-seasonal-influenza-likelihood-of-approval/ 2024-06-17T07:43:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cv-7302-curevac-influenza-a-virus-h5n1-subtype-infections-likelihood-of-approval/ 2024-06-17T07:43:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cv-7302-curevac-influenza-a-virus-h1n1-subtype-infections-likelihood-of-approval/ 2024-06-17T07:42:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/setanaxib-calliditas-therapeutics-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2025-01-22T16:37:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T16:37:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T16:37:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-esophageal-cancer-likelihood-of-approval/ 2025-01-22T16:36:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tamibarotene-toko-pharmaceutical-industries-polycystic-kidney-disease-likelihood-of-approval/ 2024-06-17T07:41:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azeliragon-cantex-pharmaceuticals-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T16:36:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrexafungerp-citrate-gsk-systemic-candidiasis-likelihood-of-approval/ 2025-01-22T16:36:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrexafungerp-citrate-gsk-blastomycosis-likelihood-of-approval/ 2025-01-22T16:36:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrexafungerp-citrate-gsk-histoplasmosis-likelihood-of-approval/ 2025-01-22T16:36:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrexafungerp-citrate-gsk-candidiasis-likelihood-of-approval/ 2025-01-22T16:36:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrexafungerp-citrate-gsk-aspergillosis-likelihood-of-approval/ 2025-01-22T16:36:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrexafungerp-citrate-gsk-coccidioidomycosis-likelihood-of-approval/ 2025-01-22T16:36:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrexafungerp-citrate-gsk-fungal-infections-likelihood-of-approval/ 2025-01-22T16:36:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirdametinib-springworks-therapeutics-low-grade-glioma-likelihood-of-approval/ 2024-06-17T07:37:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tg-1042-ascend-biopharmaceuticals-cutaneous-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T16:36:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tg-1042-ascend-biopharmaceuticals-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2025-01-22T16:36:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-primary-cns-lymphoma-likelihood-of-approval/ 2025-01-22T16:36:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-leukemia-likelihood-of-approval/ 2025-01-22T16:36:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-22T16:36:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cebranopadol-tris-pharma-chronic-low-back-pain-clbp-likelihood-of-approval/ 2025-01-22T16:36:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cebranopadol-tris-pharma-opium-opioid-addiction-likelihood-of-approval/ 2025-01-22T16:36:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cebranopadol-tris-pharma-pain-likelihood-of-approval/ 2025-01-22T16:36:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avicursen-percheron-therapeutics-duchenne-muscular-dystrophy-likelihood-of-approval/ 2025-01-22T16:36:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ep-0057-ellipses-pharma-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T16:35:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipifarnib-kura-oncology-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-22T16:35:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipifarnib-kura-oncology-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T16:35:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:35:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-22T16:35:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabedersen-oncotelic-therapeutics-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-06-17T07:33:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levosimendan-orion-subarachnoid-hemorrhage-likelihood-of-approval/ 2024-07-05T18:54:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teverelix-antev-urinary-retention-likelihood-of-approval/ 2024-06-17T07:32:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levonadifloxacin-wockhardt-gram-positive-bacterial-infections-likelihood-of-approval/ 2024-06-17T07:32:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lumateperone-tosylate-intra-cellular-therapies-major-depressive-disorder-likelihood-of-approval/ 2025-01-22T16:35:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rigosertib-sodium-traws-pharma-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:35:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rigosertib-sodium-traws-pharma-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-22T16:35:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rigosertib-sodium-traws-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:35:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropeginterferon-alfa-2b-la-pharmaessentia-lymphoma-likelihood-of-approval/ 2025-01-22T16:35:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bc-7013-nabriva-therapeutics-skin-and-skin-structure-infections-sssi-likelihood-of-approval/ 2024-06-17T07:29:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lefamulin-acetate-nabriva-therapeutics-complicated-skin-and-skin-structure-infections-csssi-likelihood-of-approval/ 2024-09-09T06:31:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lefamulin-acetate-nabriva-therapeutics-cystic-fibrosis-likelihood-of-approval/ 2024-09-09T06:30:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipiracil-hydrochloride-trifluridine-les-laboratoires-servier-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T16:35:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipiracil-hydrochloride-trifluridine-taiho-oncology-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-22T16:35:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sotevtamab-alethia-biotherapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-17T07:27:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-ipsen-gastric-cancer-likelihood-of-approval/ 2025-01-22T16:35:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bremelanotide-acetate-cosette-pharmaceuticals-diabetic-nephropathy-likelihood-of-approval/ 2025-01-22T16:34:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anakinra-swedish-orphan-biovitrum-hospital-acquired-pneumonia-hap-likelihood-of-approval/ 2025-01-22T16:34:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anakinra-swedish-orphan-biovitrum-community-acquired-pneumonia-likelihood-of-approval/ 2025-01-22T16:34:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olamkicept-ferring-international-center-ulcerative-colitis-likelihood-of-approval/ 2025-01-22T16:34:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aflibercept-regeneron-pharmaceuticals-optic-neuropathy-likelihood-of-approval/ 2025-01-22T16:34:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aflibercept-regeneron-pharmaceuticals-graves-ophthalmopathy-likelihood-of-approval/ 2025-01-22T16:34:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval-2/ 2025-01-22T02:00:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval-2/ 2025-01-22T02:00:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-22T16:34:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-bladder-cancer-likelihood-of-approval-2/ 2025-01-22T02:00:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-gastric-cancer-likelihood-of-approval-2/ 2025-01-22T02:00:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-cervical-cancer-likelihood-of-approval-2/ 2025-01-22T02:00:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/methylnaltrexone-bromide-bausch-health-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-06-17T07:22:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zotiraciclib-citrate-beijing-zhikangbo-medical-oncology-research-high-grade-glioma-likelihood-of-approval/ 2025-01-22T16:33:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-22T16:33:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:33:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-22T02:24:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-chondrosarcoma-likelihood-of-approval/ 2024-06-17T07:20:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-melanoma-likelihood-of-approval/ 2025-01-22T02:24:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/derazantinib-hydrochloride-basilea-pharmaceutica-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-06-17T07:19:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brilacidin-alfasigma-proctitis-likelihood-of-approval/ 2025-01-22T02:24:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clazakizumab-csl-end-stage-kidney-disease-end-stage-renal-disease-or-esrd-likelihood-of-approval/ 2025-01-22T02:24:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-22T02:23:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/everolimus-novartis-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-22T02:23:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abatacept-bristol-myers-squibb-myocarditis-likelihood-of-approval/ 2025-01-22T02:23:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifamycin-sodium-cr-cosmo-pharmaceuticals-bacterial-infections-likelihood-of-approval/ 2025-01-22T02:23:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-albumin-bound-bristol-myers-squibb-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-06-17T07:16:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-albumin-bound-bristol-myers-squibb-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-06-17T07:16:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tezepelumab-amgen-granulomatosis-with-polyangiitis-wegener-s-granulomatosis-likelihood-of-approval/ 2025-01-22T02:23:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tezepelumab-amgen-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2025-01-22T02:23:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belumosudil-mesylate-sanofi-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-22T02:23:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belumosudil-mesylate-sanofi-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-22T02:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belumosudil-mesylate-sanofi-lung-transplant-rejection-likelihood-of-approval/ 2025-01-22T02:23:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T02:23:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-samyang-biopharmaceuticals-esophageal-cancer-likelihood-of-approval/ 2024-07-05T18:52:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-samyang-biopharmaceuticals-cervical-cancer-likelihood-of-approval/ 2024-06-17T07:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-chugai-pharmaceutical-septic-shock-likelihood-of-approval/ 2025-01-22T02:23:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-chugai-pharmaceutical-sepsis-likelihood-of-approval/ 2025-01-22T02:23:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/canakinumab-novartis-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2025-01-22T02:23:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/canakinumab-novartis-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-22T02:23:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-22T02:23:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T02:23:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-ovarian-cancer-likelihood-of-approval/ 2025-01-22T02:23:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/panobinostat-pharmaand-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-06-17T06:50:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itolizumab-equillium-lupus-nephritis-likelihood-of-approval/ 2025-01-22T02:23:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enzalutamide-pfizer-breast-cancer-likelihood-of-approval/ 2025-01-22T02:22:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-22T02:22:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:22:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-22T02:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2025-01-22T02:22:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-laryngeal-cancer-likelihood-of-approval/ 2025-01-22T02:22:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:22:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrutinib-abbvie-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T02:22:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T02:22:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-22T02:22:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mecasermin-rinfabate-chiesi-farmaceutici-bronchopulmonary-dysplasia-likelihood-of-approval/ 2025-01-22T02:22:27+00:00 daily 0.2